Pioneering the development
of engineered IgM antibodies



Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants

Published in Nature, 03 June 2021 Citation: Ku, Z., Xie, X., Hinton, P.R. et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature (2021)…

Pharmacodynamic Assessment of an IgM Antibody Using BRGSF-HIS Mice

Predict Innovation — May 20, 2021

Next-Generation Approaches to COVID-19 Therapeutics: Clinical Challenges and Engineering Solutions

PEGS Boston – May 11-13, 2021 Session: Novel and Alternative Approaches to Developing Covid-19 Therapeutics – May 11, 2021

Engineering the Future: Next Gen Platforms in Oncology

Cancer Progress Virtual – May 4-6, 2021 Keynote Address – May 4, 2021

Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo

Triple Negative Breast Cancer Drug Development Digital Summit – April 28-29, 2021 Session: Uncovering the Latest Targeted Therapy Approaches – April 29, 2021

Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity

AACR Annual Meeting 2021 Virtual – April 10-15, 2021 Session: Therapeutic Mechanisms of Novel Anticancer Agent, Abstract No. 52

Clinical Challenges and Engineering Solutions in Cancer Immunotherapy: What Do We Need Now?

Nature Research Webcast: Immuno-oncology: IgG and Beyond – April 6, 2021

Potent Anti-Tumor Activity of IGM-8444, an Agonist DR5 IgM, Displays Strong Synergy with Chemotherapy and Inducers of Apoptosis

Festival of Biologics USA – March 29 to April 1, 2021

Delivery of IL-15 to PD-L1 Expressing Tumors with an Anti-PD-L1 IgM

Cytokine-Based Cancer Immunotherapies Summit – March 24-25, 2021

In the Media: Nature Biotechnology – Bispecific Antibodies Poised to Deliver Wave of Cancer Therapies

Citation: Sheridan, C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol 39, 251–254 (2021)